19:52 , Jul 13, 2018 |  BC Week In Review  |  Financial News

French Orphan company Dynacure raises €47M

Dynacure S.A.S. (Illkirch, France) raised €47 million ($54.7 million) in a venture round led by Andera Partners. Founding investor Kurma Partners S.A. also participated, as did existing investor Bpifrance and new investors Pontifax and IdInvest...
10:25 , Jul 6, 2018 |  BC Extra  |  Financial News

French Orphan company Dynacure raises €47M

Dynacure S.A.S. (Illkirch, France) raised €47 million ($54.7 million) in a venture round led by Andera Partners. Founding investor Kurma Partners S.A. also participated, as did existing investor Bpifrance and new investors Pontifax and IdInvest...
10:22 , Jul 6, 2018 |  BioCentury  |  Finance

Dynacure’s quick transfer

A new €47 million ($54.7 million) round will allow Dynacure S.A.S. to begin clinical testing of its lead program to treat centronuclear myopathy (CNM) less than three years after its inception. The round is also...
19:18 , Nov 17, 2017 |  BC Week In Review  |  Company News

Ionis grants Dynacure rights to musculoskeletal candidate IONIS-DNM2-2.5Rx

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted Dynacure S.A.S. (Illkirch, France) rights to develop and commercialize IONIS-DNM2-2.5Rx (DYN101). Dynacure is developing the antisense oligonucleotide targeting the mRNA of dynamin 2 (DNM2) to treat centronuclear myopathy (CNM), a...
13:08 , Jun 21, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Musculoskeletal Mouse studies suggest antisense oligonucleotides (ASOs) against DNM2 could help treat X-linked centronuclear myopathies. In a myotubularin 1 (MTM1)-knockout mouse model of X-linked centronuclear myopathy, intramuscular injection of an ASO targeting mouse DNM2...
01:10 , May 13, 2017 |  BioCentury  |  Emerging Company Profile

Dialing down dynamin

Dynacure S.A.S. is developing an antisense oligonucleotide against DNM2 that could treat all three subtypes of centronuclear myopathy, two of which are not covered by industry’s pipeline. Centronuclear myopathy (CNM) is a group of rare...
15:50 , Feb 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Bladder cancer In vitro studies suggest inhibiting DNM2 could help treat metastatic bladder cancer. In a human bladder cancer cell line, a DNM2 inhibitor tool compound or siRNA targeting DNM2 decreased formation of invadopodia...
21:03 , Jan 19, 2017 |  BC Innovations  |  Finance

Kurma chameleon

French life science VC Kurma Partners S.A. is experimenting with a new investment model to accelerate the transfer of European academic research into the commercial setting with less risk than standard seed investments. The firm...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

Ionis Pharmaceuticals, Dynacure deal

Ionis and newco Dynacure partnered to use Ionis’ antisense platform to discover a treatment for rare centronuclear myopathies targeting dynamin 2 (DNM2) . Dynacure was spun out of the Institute of Genetics and Molecular and...